Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

FORGOTTEN HISTORY: 15 - Caught on Camera

10 Biggest Price Target Changes For Thursday

Needham lowered MKS Instruments, Inc. (NASDAQ: MKSI) price target from $185 to $175. MKS Instruments shares rose 3.6% to $116.01 in pre-market trading.

Needham Maintains Buy Rating for Calix: Here's What You Need To Know

Needham Maintains Buy Rating for Calix: Here's What You Need To Know

Needham has decided to maintain its Buy rating of Calix (NYSE:CALX) and lower its price target from $73.00 to $60.00. Shares of Calix are trading up 3.28% over the last 24 hours, at $39.34 per share. A move to $60.00 would account for a 52.52% increase from the current share…

Here's Why Analysts Were Impressed Post Cadence Design Systems' Q1 Performance

Here's Why Analysts Were Impressed Post Cadence Design Systems' Q1 Performance

Cadence Design Systems, Inc (NASDAQ:CDNS) impressed analysts post Q1 beat. Baird reiterated Outperform rating on Cadence, adjudging it as a top idea. All business groups saw strength, with recurring revenues increasing 19% YoY (led by Digital and System Design) and upfront revenues rising 49% YoY. FY22 outlook raised given 1Q strength, upside in 2Q,…

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

These Netflix Analysts Aren't Confident Of A Turnaround Within The Next 18 Months

Netflix Inc (NASDAQ: NFLX) reported a revenue miss and a loss of net paid adds for the first quarter.

Coinbase And This Cold Wallet Stock Look 'Quite Discounted' Ahead Of Potential Crypto Rally

Bitcoin (CRYPTO: BTC) is down about 10% year-to-date, but several crypto-related stocks have fallen significantly further. Needham & Company's John Todaro offered an explanation for the disconnection Tuesday on CNBC's "TechCheck."

Needham Estimates PhaseBio Pharma's Bentracimab Market Opportunity Of Up To $1.5B

PhaseBio Pharmaceuticals Inc (NASDAQ: PHAS) remains on track to complete the bentracimab biologics license application (BLA) filing around mid-2022 for bleeding risks associated with using ticagrelor antiplatelet drug.

Here's What Made Needham Bullish On This CyberSecurity Company

Needham hosted CrowdStrike Holdings Inc (NASDAQ:CRWD) on its first in-person NDR since COVID started. It had a Buy rating with a $340 (51.6% upside) price target. CrowdSrike developed the critical elements of technology with an integrated vision of a trustworthy Cloud-Native Security platform, from the lightweight agent with the embedded Threat Graph to the…

inkl

Read news from The Economist, FT, and more,
with one subscription

Merit Medical Bullish On FY23 Operating Margin Of 18-21%, Needham Says Could Exceed

Merit Medical Bullish On FY23 Operating Margin Of 18-21%, Needham Says Could Exceed

At the Annual Needham Healthcare Conference, Merit Medical Systems Inc's (NASDAQ: MMSI) management said that inflationary pressures and supply chain issues have been manageable and have not had a material impact on its results year-to-date.

Here's What Made Needham Bullish On Nvidia, AMD Versus Others In Semiconductor Space

Here's What Made Needham Bullish On Nvidia, AMD Versus Others In Semiconductor Space

Needham shifted its focus on NVIDIA Corp (NASDAQ: NVDA) and Advanced Micro Devices Inc (NASDAQ: AMD).

Deutsche Bank Sees Netflix In Line With 2.5M Subscriber Guidance

Deutsche Bank Sees Netflix In Line With 2.5M Subscriber Guidance

Deutsche Bank analyst Bryan Kraft maintained his Q1 global subscriber estimate, in line with Netflix Inc's (NASDAQ:NFLX) 2.5 million guidance amid cutthroat competition and Covid resurgence. He saw net adds inching closer to 3.5 million when not accounting for Russia's 1 million base adjustment. Also Read: Needham Sees Netflix Losing Out To Amazon, Disney, Apple and…

Phathom Pharma's Vonoprazan Commercial Preparation Update At Needham Healthcare Conference

Phathom Pharma's Vonoprazan Commercial Preparation Update At Needham Healthcare Conference

At the Needham Healthcare Conference, Phathom Pharmaceuticals Inc (NASDAQ:PHAT) says that licensor Takeda Pharmaceutical Co Ltd (NYSE: TAK) reported Takecab (vonoprazan) Q4 FY21 sales of $221 million and $900 million in FY21. Phathom estimates that around 30% is from erosive esophagitis (EE), approximately 60% is from gastroesophageal reflux disease (GERD)/other, and less than 10% is…

Bitcoin Miami 2022 Showed An Institutional Shift, Says Analyst

Bitcoin Miami 2022 Showed An Institutional Shift, Says Analyst

Following the conclusion of the 2022 Bitcoin (CRYPTO: BTC) conference held in Miami, Florida, an analyst at Needham shared his key takeaways.

Needham Sees Clear View Into STAAR Surgical's Durable Double-Digit Revenue Expansion

Needham Sees Clear View Into STAAR Surgical's Durable Double-Digit Revenue Expansion

Needham is initiating coverage on STAAR Surgical Company (NASDAQ:STAA) with a Buy rating and an $87 price target. The analysts note that FDA approval of STAA's EVO Implantable Collamer Lens (ICLs) should serve as a meaningful tailwind for revenue. The Company generates most of its revenue from outside US markets. But after the FDA approval…

Read Why Needham Is Bullish On This Pet Retailer

Read Why Needham Is Bullish On This Pet Retailer

Needham analyst Anna Andreeva gave Petco Health And Wellness Co Inc (NASDAQ:WOOF) a Buy rating with a price target of $30.00 (45% upside). Andreeva notes Petco is becoming an omni-channel powerhouse after revamping its digital capabilities under CEO Ron Coughlin. The analyst thinks that the company’s bundled offerings model has a significant advantage over digital-only players. Petco…

Get all your
news in one place.

100's of premium titles.
One news app.

Needham Initiates Alcon Citing 'Visible Path to Sustainable Double-Digit EPS Growth'

Needham is initiating coverage on Alcon AG (NYSE: ALC) with a Buy rating and

Benzinga's Top Ratings Upgrades, Downgrades For April 8, 2022

Medtronic's Portfolio Management Unlikely To Be A 'Magic Bullet,' Says Needham

Needham published a report that pointed to previous comments from Medtronic plc's (NYSE: MDT) management that indicate the potential for changes in the coming year, with a spinoff of a large business considered an option.

Here's How Analysts View Analog Devices Post Investor Day

Analog Devices Inc (NASDAQ:ADI) highlighted its strategic vision and new financial model at its investor day meet. Piper Sandler analyst Harsh Kumar reiterated an Overweight with a $210 price target (30% upside). Kumar expects the company to benefit from several secular growth drivers within the semiconductor industry. Related: Analog Devices Tops Q1 Backed By Momentum Across…

Get all your
news in one place.

100's of premium titles.
One news app.

Analysts Continue To See Sharp Upside In SMART Global Post Q2 Results

Analysts had a mixed take on SMART Global Holdings Inc (NASDAQ:SGH) post Q2 results. Needham analyst Ravindra Gill raised the price target to $45 (89% upside) with a Buy rating following the seventh consecutive beat raise quarter. SGH remains the firm's Top Pick for 2022. SGH's commercial and government customers have already designed and contracted the…

Needham Halves Price Target On Shapeways Post Q4 Results

Needham analyst James Ricchiuti reduced the price target on Shapeways Holdings Inc (NYSE: SHPW) to $5 (an upside over 100%) from $10 while still keeping the Buy rating on the shares.

Needham Cuts Wayfair Price Target By 17%

Needham analyst Anna Andreeva lowered the price target on Wayfair Inc (NYSE:W) to $150 from $180 and maintained a Buy rating on the shares, implying a 37% upside. The analyst noted that the company's near-term trends remain under pressure amidst a volatile macro backdrop. Andreeva specified that Wayfair has a 2.4% penetration in its largest market,…

Netflix Snaps Its Third Gaming Studio

Netflix Inc (NASDAQ:NFLX) acquired Boss Fight Entertainment, a mobile game developing studio, Venture Beat reports. The financial terms of the transaction remain undisclosed. Boss Fights joined Netflix's two other game studio acquisitions after Night School Studio and Next Games, Variety reports. Also Read: Needham Sees Netflix Losing Out To Amazon, Disney, Apple and Other Streaming Rivals…

Coinbase Analyst Spells Bull Case: Forcasts $1.26B Additional Revenue From NFTs Alone

Needham analyst John Todaro has outlined a bullish scenario for Coinbase Global Inc (NASDAQ: COIN) if its upcoming non fungible token (NFT) business takes off as planned.

Why This Revolve Group Analyst Says Online Fashion Retailer Is A Buy

Revolve Group Inc (NYSE: RVLV) is “an ultimate reopening play” and the Street's sales growth estimate of 35% for the first half of the year in 2022 appears conservative, according to Needham.

Amazon Consummates MGM Deal Post Clean Chit From Regulators

Amazon.com Inc (NASDAQ:AMZN) closed the $8.5 billion acquisition of film studio Metro-Goldwyn-Mayer after a clean chit from the U.S. FTC and EU. The EU contended that the deal would not hamper competition as the two companies did not significantly overlap in content production, the Wall Street Journal reports. The FTC also did not…

1 … 13 14 15 16

People

Justin Patterson

Barton Crockett

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Amazon.com Inc.

Wall Street Journal

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

388,037 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play